Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are comparing AZD0901 with standard treatments in people with advanced gastric cancer. The people in this study have cancer of the stomach or the junction between the esophagus and stomach (gastroesophageal junction). The people in this study have cancers that make a protein called Claudin18.2 (CLDN18.2).
The purpose of this study is to find the highest dose of the investigational drug AVA6000 that can be given safely in people with advanced solid tumors that are not responding to treatment. AVA6000 is very similar to a standard chemotherapy drug called doxorubicin. Like doxorubicin, AVA6000 works to slow or stop the growth of cancer cells by blocking an enzyme. Unlike doxorubicin, however, AVA6000 is a "prodrug," meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein).
Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.
Researchers want to see if a test for cancer DNA in the blood helps doctors decide whether to reduce Hodgkin lymphoma chemotherapy. The blood test is a circulating tumor DNA (ctDNA) test called Foresight CLARITY. ctDNA is genetic material released by tumor cells directly into the bloodstream.
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and begin to attack them.
Researchers want to see if disitamab vedotin plus tucatinib is safe and works well in people with advanced solid tumors. They want to find the best dose of disitamab vedotin to give with tucatinib. The people in this study have different types of HER2-positive and HER2-low solid tumors, including breast cancer.
The usual approach to managing HPV-related oropharynx cancer in people whose tumors have a higher risk of coming back after surgery is to use radiation therapy to prevent tumor relapse. However, not all patients have tumors that come back after surgery, and many may not need radiation therapy at all, or only need it later when there are early signs of the cancer coming back.
Researchers want to find the best dose of Debio 0123 that can be given with temozolomide to treat glioblastoma. Glioblastoma is a type of brain cancer. The people in this study have glioblastoma that keeps growing even after treatment.
Researchers are assessing a combination of medications to see if they work well against upper digestive cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that spread and keep growing after treatment.
Researchers are seeking the best dose of cirtuvivint to use alone and with ASTX727 for leukemia and myelodysplastic syndromes (MDS). The people in this study have acute myeloid leukemia (AML) or MDS that keeps growing after treatment.
